Evidence map›Paper›PMID 38536619›Full record

ArticleJournal of epidemiology and global health2024

Acceptability and Feasibility of the Plasma Separation Card for an Integrated Model of Care for HBV and HCV Screening Among People Attending HIV Clinics in Cameroon and Uganda.

Camila A Picchio, Aina Nicolàs, Ironne Valdèse Ayemfouo Fofou, Viola Kasone, Magellan Guewo-Fokeng, Claude T Tagny, Teddy Nanyonjo, Hellen Nansumba, Yves Nacel Kouongni, Rita Gaëlle Epse Sezawo Kamdjeu and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of epidemiology and global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Dried Spot Paradigm: Problems and Prospects in Proteomics.International journal of molecular sciences · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 4 countries.

Camila A PicchioBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain. camila.picchio@isglobal.org.ORCID http://orcid.org/0000-0002-0321-662X
Aina NicolàsBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0009-0002-1841-8133
Ironne Valdèse Ayemfouo FofouDepartment of Biochemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.
Viola KasoneCentral Public Health Laboratories, Ministry of Health of Uganda, Kampala, Uganda.
Magellan Guewo-FokengDepartment of Biochemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.
Claude T TagnyHematology and Blood Transfusion Unit, University Teaching Hospital of Yaoundé, Yaoundé, Cameroon.ORCID http://orcid.org/0000-0002-2179-3105
Teddy NanyonjoCentral Public Health Laboratories, Ministry of Health of Uganda, Kampala, Uganda.
Hellen NansumbaCentral Public Health Laboratories, Ministry of Health of Uganda, Kampala, Uganda.ORCID http://orcid.org/0000-0002-2421-0606
Yves Nacel KouongniHematology and Blood Transfusion Unit, University Teaching Hospital of Yaoundé, Yaoundé, Cameroon.
Rita Gaëlle Epse Sezawo KamdjeuHematology and Blood Transfusion Unit, University Teaching Hospital of Yaoundé, Yaoundé, Cameroon.
Emmanuel SerembaKiruddu National Referral Hospital, Kampala, Uganda.
Charles KouanfackDay Hospital, HIV Care and Treatment Unit, Yaoundé Central Hospital, Yaoundé, Cameroon.
Isaac SsewanyanaCentral Public Health Laboratories, Ministry of Health of Uganda, Kampala, Uganda.
Richard NjouomCentre Pasteur of Cameroon, Yaoundé, Cameroon.ORCID http://orcid.org/0000-0003-3112-6370
Ariadna Rando SeguraDepartment of Microbiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.
Francisco Rodríguez-FríasLiver Pathology Unit, Department of Biochemistry, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Jean Claude Mbanya *Laboratory of Molecular Medicine and Metabolism, Biotechnology Centre, University of Yaoundé I, Yaoundé, Cameroon.ORCID http://orcid.org/0000-0001-9651-8653
Ponsiano Ocama *College of Health Sciences, Makerere University, Kampala, Uganda.ORCID http://orcid.org/0000-0002-6120-1055
Jeffrey V Lazarus *Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9618-2299
Ministry of Health · UGUniversité de Yaoundé I · CMUniversity Teaching Hospital of Yaounde · CMBarcelona Institute for Global Health · ESCentre Pasteur du Cameroun · CMInstituto de Salud Carlos III · ESMakerere University · UGThe Graduate Center, CUNY · USUniversité de Dschang · CMVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSub-Saharan African countries have a high burden of viral hepatitis and poor access to screening and care. The aim of this study was to evaluate the feasibility and acceptability of using the plasma separation card (PSC) for viral hepatitis B and C screening among people living with HIV (PLHIV) in Cameroon and Uganda.

methodsThis is a cross-sectional study carried out between 05/2021 and 03/2023 including 192 PLHIV in Cameroon (n = 104) and Uganda (n = 88). Basic sociodemographic variables and whole blood samples were collected. Adequate filling with blood of PSCs was used to determine feasibility together with participant responses to questions on acceptability. A logistic regression model was carried out to assess the relationship between PSC acceptability and factors of interest.

results70% of participants reported PSC as an acceptable viral hepatitis screening tool, and it was significantly more accepted in Uganda than Cameroon (100% vs. 43.2%, p < 0.001). Similarly, 75% of PSCs had at least one spot sample filled and were viable for analysis, 99% were correctly filled in Uganda and 53.4% in Cameroon. Reported ease of method performance (aOR: 24.77 95% CI 2.97-206.42, p = 0.003) and reduced collection time (aOR: 3.73 95% CI 1.26-11.04, p = 0.017) were associated with greater odds of PSC acceptance. HBsAg + and anti-HCV + prevalence were 11.1% and 1.0%, respectively.

conclusionsIn spite of country differences, overall, the PSC was reported as a feasible and acceptable viral hepatitis testing method. Acceptability and feasibility of the method must be explored in heterogeneous target communities and qualitative research to better understand country-specific barriers and facilitators should be carried out.

Indexed as

Feasibility StudiesHepatitis BHepatitis CHIV InfectionsMass ScreeningAdultCameroonCross-Sectional StudiesFemaleHumansMaleMiddle AgedPatient Acceptance of Health CareUgandaCameroonDried blood spotHepatitis BPlasma separation cardUgandaViral hepatitis testing

Identifiers

PMID38536619
PMCPMC11442892
OpenAlexW4393225274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.